Oral Clofarabine for Acute Myeloid Leukemia

Phase 1 Completed 25 enrolled Washington University School of Medicine

Non-randomizedParallel-groupOpen-labelTreatment

This is a phase I study designed to test the safety of oral clofarabine when given as consolidation therapy to older patients with AML in remission.

Evaluation	Drug	Modality	Dose	Route
Subject	Clofarabine	Other / unclassified	1 mg	Oral
Subject	Clofarabine	Other / unclassified	2 mg	Oral
Subject	Clofarabine	Other / unclassified	3 mg	Oral
Subject	Clofarabine	Other / unclassified	4 mg	Oral
Subject	Clofarabine	Other / unclassified	5 mg	Oral
Subject	Clofarabine	Other / unclassified	6 mg	Oral